[Skip to Content]
[Skip to Content Landing]
Views 2,298
Citations 0
April 2, 2019

Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment

Author Affiliations
  • 1Department of Radiology, Mayo Clinic, Rochester, Minnesota
  • 2Department of Neurology, Mayo Clinic, Rochester, Minnesota
JAMA. 2019;321(13):1258-1260. doi:10.1001/jama.2019.1998

In this issue of JAMA, Rabinovici and colleagues present the results of The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study.1 The study had its origins in the 2013 decision by the US Centers for Medicare & Medicaid Services (CMS) that current evidence was insufficient to warrant coverage of amyloid positron emission tomography (PET) scanning for routine clinical care. However, in that decision, CMS agreed to provide coverage with evidence development in studies that would examine whether amyloid PET improved health outcomes in Medicare and Medicaid beneficiaries. Given that no disease-modifying treatments have yet been approved, health outcomes that can be assessed at this time are those related to diagnostic test ordering, symptomatic treatment decisions, or counseling, and these are the outcomes assessed in IDEAS.